{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/insomnia/management/managing-long-term-insomnia-greater-3-months/","result":{"pageContext":{"chapter":{"id":"9c9c0f54-a495-58d5-9a6f-00b3ea587356","slug":"managing-long-term-insomnia-greater-3-months","fullItemName":"Scenario: Managing long-term insomnia (> 3 months)","depth":2,"htmlHeader":"<!-- begin field 1c68b3ef-c993-4055-a68d-f068bab4de35 --><h2>Scenario: Managing long-term insomnia (more than 3 months duration)</h2><!-- end field 1c68b3ef-c993-4055-a68d-f068bab4de35 -->","summary":"Covers the management of people with long-term insomnia in primary care.","htmlStringContent":"<!-- begin item ed378768-f7a5-460d-b5e5-23604b838802 --><!-- begin field 22d00991-7820-462d-85a8-acbc0158b962 --><p>From age 16 years onwards.</p><!-- end field 22d00991-7820-462d-85a8-acbc0158b962 --><!-- end item ed378768-f7a5-460d-b5e5-23604b838802 -->","topic":{"id":"d32ed400-7d0f-58c1-b35a-07cabeb7198f","topicId":"c95c9c90-991c-42bf-9bb6-260f08eb9d32","topicName":"Insomnia","slug":"insomnia","lastRevised":"Last revised in January 2020","chapters":[{"id":"99b2443e-da9c-5c9d-8066-cea961d77010","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"775bdb91-759e-5182-aa24-3faa2be61175","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4b1bac5b-de37-521d-afa3-7222f1f8a344","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"079ebee9-04a4-5115-ad9d-4ec64285cafe","slug":"changes","fullItemName":"Changes"},{"id":"fadd9470-736e-56b5-9e47-fabc4c25c40a","slug":"update","fullItemName":"Update"}]},{"id":"6d4dc1da-3cad-586f-9720-807538e37ae0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"dd70908f-732c-56f4-96ee-63c1a0d48b93","slug":"goals","fullItemName":"Goals"},{"id":"7c916994-5730-5df1-a42d-0903da669227","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3babc745-3146-54d7-a591-229458269920","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c9a1ae6b-b43f-5001-9ce6-eec4fe6a51d6","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"782e1bf0-98b1-5461-be78-dcabc4e8768b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bf1c4d94-7a24-5b6b-b08e-2e91d584da67","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f99b4301-f0d0-5b2d-9c5d-5448b2c5ae71","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e829a9d8-9a8a-5fff-acc0-b36a76b06365","slug":"definition","fullItemName":"Definition"},{"id":"71bd7cfa-09cb-59bc-8596-cf8b380bdfc8","slug":"causes","fullItemName":"Causes"},{"id":"d3f6ead4-def6-5d80-82da-6a216bbf5205","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a96dbcb1-2be5-5896-958a-015d9d9ff705","slug":"prognosis","fullItemName":"Prognosis"},{"id":"d70599ab-d67b-56eb-a550-5eb50783af51","slug":"complications","fullItemName":"Complications"}]},{"id":"908b4222-ad0d-5cb4-b245-b6613b9935af","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1ef90db4-827f-5f00-89c3-71b0b81deeed","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"db78ccd5-ae24-5f11-9afb-47d56a4e8c1a","slug":"assessment","fullItemName":"Assessment"},{"id":"e1f82dba-1dd1-5cd6-89fd-df0bb7eea4b2","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0b989149-2d7c-55da-a785-3b93e4e9e30d","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d6f6f9c-bb55-5871-81f4-30b4b0e1e3ce","slug":"managing-short-term-insomnia-less-3-months","fullItemName":"Scenario: Managing short-term insomnia (< 3 months)"},{"id":"9c9c0f54-a495-58d5-9a6f-00b3ea587356","slug":"managing-long-term-insomnia-greater-3-months","fullItemName":"Scenario: Managing long-term insomnia (> 3 months)"}]},{"id":"d5ba983f-3e5f-57df-9f8b-dcf81a11b4e9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"34ae23e7-59a3-54c1-80f6-944b0b43d4c4","slug":"z-drugs","fullItemName":"Z-drugs"},{"id":"c581c21d-a147-50d8-8437-df289bb720bf","slug":"melatonin","fullItemName":"Melatonin"}]},{"id":"787787e5-4b3f-5665-bb53-35fba2334669","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"248c0d90-0e6b-5fc7-b6ab-94f0aca25c78","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"964993b0-a6a2-584e-b2b2-1d307e45d4a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4fc22a18-8f09-58a9-aaf9-e4d181a88b4b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3eed36c6-8b0c-5776-aa33-aba8181960d9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e9c29199-597b-5045-bb8e-91f46f5641cc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"54861215-5c9f-5992-83e2-44e0d123cd39","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"40987924-ac87-5c7f-8d13-d6233cd2729a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0b989149-2d7c-55da-a785-3b93e4e9e30d","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"0ea77193-5148-53f0-84b8-a57dbe4f2d9d","slug":"long-term-insomnia-greater-3-months","fullItemName":"Long-term insomnia (> 3 months)","depth":3,"htmlHeader":"<!-- begin field 100c383f-b943-4b40-a192-12638b50adce --><h3>How should I manage someone with long-term insomnia (more than 3 months duration)?</h3><!-- end field 100c383f-b943-4b40-a192-12638b50adce -->","summary":null,"htmlStringContent":"<!-- begin item bf3e2ae4-d320-45ff-9dc2-e33aa2262eba --><!-- begin field 91f3f8e8-1fe7-450a-b8c8-a9d2f85e84f9 --><ul><li>Consider the need for <a class=\"topic-reference internal-reference\" href=\"/topics/insomnia/management/managing-long-term-insomnia-greater-3-months/#referral\">referral</a> to a sleep clinic or neurology if symptoms of <a class=\"topic-reference internal-reference\" href=\"/topics/insomnia/diagnosis/differential-diagnosis/\">another sleep disorder</a> are present.</li><li>Address any triggers or factors associated with maintenance of insomnia (for example illness or other stressors).<ul><li>Ensure comorbidities (such as anxiety and depression) are optimally managed.</li></ul></li><li>Offer advice on <a class=\"topic-reference internal-reference\" href=\"/topics/insomnia/management/managing-short-term-insomnia-less-3-months/#good-sleep-hygiene\">sleep hygiene</a>. </li><li>Advise the person not to drive if they feel sleepy.<ul><li>The DVLA must be informed if excessive sleepiness is having, or is likely to have, an adverse effect on driving including:<ul><li>Obstructive sleep apnoea syndrome (any severity).</li><li>Primary/central hypersomnias (such as narcolepsy).</li><li>Any other conditions or medication that may cause excessive sleepiness.</li></ul></li><li>For more detailed guidance, see the DVLA '<a href=\"https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/834504/assessing-fitness-to-drive-a-guide-for-medical-professionals.pdf\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"cc419059-4bd1-4108-bfe3-ab5300a6c513\">At a glance</a>' guide.</li></ul></li><li>Offer cognitive behavioural therapy for insomnia (CBT-I) as the first-line treatment for chronic insomnia in adults of any age.<ul><li>CBT-I typically includes behavioural interventions (such as stimulus control and sleep restriction), cognitive therapy and relaxation training. It can be provided face-to-face or digitally.</li></ul></li><li>Pharmacological therapy should be avoided in the long-term management of insomnia, however:<ul><li>For some people with severe symptoms or an acute exacerbation a short course of a hypnotic drug (preferably less than 1 week) may be considered as a temporary adjunct to behavioural and cognitive treatment.<ul><li>For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/insomnia/management/managing-short-term-insomnia-less-3-months/#short-term-insomnia-less-3-months\">Management of short-term-insomnia</a>. </li><li>Do not prescribe long-term hypnotic treatment — for information on withdrawal of hypnotic medication, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/benzodiazepine-z-drug-withdrawal/\">Benzodiazepine and z-drug withdrawal</a>. </li></ul></li><li>For people over 55 years of age with persistent insomnia, treatment with a modified-release melatonin may be considered.<ul><li>The recommended initial duration of treatment is 3 weeks. If there is a response to treatment, continue for a further 10 weeks only.</li><li>Discuss the risks (similar to those of other hypnotics including falls, and fractures) associated with melatonin treatment in the elderly.</li></ul></li></ul></li><li>Provide patient information on insomnia such as:<ul><li>Mental Health Foundation <a href=\"http://www.mentalhealth.org.uk/file/1485/download?token=BUCq_Am1\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"bb44bb16-cac5-47d2-a6fc-ab5300a6c526\">How to... sleep better</a>.</li><li>NHS <a href=\"http://www.nhs.uk/conditions/insomnia/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"2a3c90a4-5b8e-4b04-9cfb-ab5300a6c59d\">Insomnia</a>.</li><li>Royal College of General Practitioners <a href=\"http://www.rcgp.org.uk/-/media/Insomnia-Top-Ten-Tips-v3.ashx?la=en\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"3ecd152e-58d2-4829-8699-ab5300a6c5c8\">Top tips: insomnia in adults</a>.</li></ul></li><li>Arrange follow up for review (2–4 weeks, dependant on the clinical situation).<ul><li style=\"list-style-type: none;\"><ul><li>If symptoms have not improved, reassess the person — consider <a class=\"topic-reference internal-reference\" href=\"/topics/insomnia/diagnosis/differential-diagnosis/\">alternative diagnoses</a> and the need for <a class=\"topic-reference internal-reference\" href=\"/topics/insomnia/management/managing-long-term-insomnia-greater-3-months/#referral\">referral</a>. </li></ul></li></ul></li><li>Do not recommend over-the-counter treatments for insomnia.</li></ul><!-- end field 91f3f8e8-1fe7-450a-b8c8-a9d2f85e84f9 --><!-- end item bf3e2ae4-d320-45ff-9dc2-e33aa2262eba -->","subChapters":[{"id":"b7d64e9a-e6ce-5755-a148-b1f11d928364","slug":"basis-for-recommendation-657","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 79a23b18-9b04-4f51-bbb9-a1dce6289cc0 --><h4>Basis for recommendation</h4><!-- end field 79a23b18-9b04-4f51-bbb9-a1dce6289cc0 -->","summary":null,"htmlStringContent":"<!-- begin item 6575b1c7-4e93-4734-b7e3-234c36cad2dc --><!-- begin field 187e1464-5259-4bac-98bd-74541b051ad6 --><p>The recommendations on how to manage a person with chronic insomnia are based on the clinical guidelines <em>Assessment to management of adult insomnia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Alberta Medical Association, 2015</a>], <em>Management of chronic insomnia disorder in adults: a clinical practice guideline</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Qaseem, 2016</a>], <em>European guideline for the diagnosis and treatment of insomnia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Riemann, 2017</a>] and <em>Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Sateia, 2017</a>], the American Thoracic Society Statement <em>The importance of healthy sleep. Recommendations and future priorities</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Mukherjee, 2015</a>], the Australasian Sleep Association position statement on <em>The use of psychological/behavioral treatments in the management of insomnia in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Ree, 2017</a>], the British Association for Psychopharmacology consensus statement<em> Evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Wilson, 2019</a>], the NICE Key therapeutic topic <em>Hypnotics</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019a</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Morin, 2015</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Cunnington, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Kay-Stacey, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Crain, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">BMJ Best Practice, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Davidson, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Mansfield, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Rios, 2019</a>]. </p><h5>Advice on driving</h5><ul><li>Recommendations on driving are based on guidance from the Driver and Vehicle Licensing Agency (DVLA) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">DVLA, 2019</a>]. </li><li>A new offence of driving with controlled drugs (including opioids and some hypnotics) above specified limits in the blood, came into force in March 2015. Further information 'Drugs and driving: the law’ is available at <a data-hyperlink-id=\"34211544-25f4-407c-b38b-ab5000f42bdb\" href=\"http://www.gov.uk/\">www.gov.uk</a>  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019a</a>]. </li><li>The MHRA has issued a warning about the risk of drowsiness and reduced driving ability the next day with zolpidem [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">MHRA, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019a</a>]. </li></ul><h5>Good sleep hygiene</h5><ul><li>Good sleep hygiene is widely supported as the first step in management of insomnia in current literature and clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Alberta Medical Association, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Cunnington, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">PrescQIPP, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Wilson, 2019</a>]. </li><li>In chronic insomnia sleep hygiene strategies should be used in combination with cognitive behaviour therapy for insomnia (CBT-I) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Alberta Medical Association, 2015</a>]. </li></ul><h5>Cognitive behaviour therapy for insomnia (CBT-I)</h5><ul><li>CBT-I is widely recommended in clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Alberta Medical Association, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Qaseem, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Ree, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Sateia, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Wilson, 2019</a>] as the first-line treatment for insomnia based on extensive evidence of effectiveness for sleep improvement and associated improvements in mental health, wellbeing and quality of life.</li><li>CBT-I has been shown to be superior to pharmacotherapy in both short- and long-term management of insomnia in adults of all ages — the benefits associated with CBT-I persist on completion of treatment, unlike those associated with medication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Alberta Medical Association, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Sateia, 2017</a>]. </li><li>The consensus statement from the British Association for Psychopharmacology highlights a longstanding problem with CBT-I availability. In the past CBT-I was offered face-to-face, but more recently self-help/telephone/internet-based CBT-I has become much more accessible and cost-effective [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Wilson, 2019</a>]. Most studies on effectiveness have focused on face-to-face CBT-I; however, more recent data suggests that other delivery methods are also effective [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Qaseem, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Crain, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Riemann, 2017</a>]. </li></ul><h5>Pharmacotherapy</h5><ul><li>The British Association for Psychopharmacology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Wilson, 2019</a>], the American College of Physicians [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Qaseem, 2016</a>], the Australasian Sleep Association [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Ree, 2017</a>], the American Academy of Sleep Medicine [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Sateia, 2017</a>], and the European Sleep Research Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Riemann, 2017</a>] recommend that CBT-I should be first-line treatment for chronic insomnia and that pharmacological treatment should only be used in acute severe cases or as a short-term adjunct to non-pharmacological measures [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Mansfield, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Rios, 2019</a>]. </li><li>Hypnotic medication should be used only after due consideration of non-pharmacological measures where insomnia is severe, disabling or causing the person extreme distress — the lowest dose that controls symptoms should be used (intermittently if possible) and discussion on risks and benefits must take place [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Qaseem, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Sateia, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Mansfield, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019a</a>]. </li><li>Hypnotic drugs are not recommended for long-term use due to safety concerns. Potential adverse effects include daytime sedation, poor coordination, cognitive impairment, increased risk of driving accidents, falls, development of tolerance, dependence and withdrawal, rebound insomnia, dementia and increased mortality [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">PrescQIPP, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">BNF, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Mansfield, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Wilson, 2019</a>]. </li></ul><h5>Avoid hypnotic medication in older people and women who are pregnant or breastfeeding</h5><ul><li>CBT-I has been found to be the most effective treatment for insomnia in adults of all ages — it is associated with minimal adverse effects and should be offered first-line where available [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Alberta Medical Association, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Wilson, 2019</a>]. </li><li>Hypnotics including the z–drugs should be avoided in the elderly due to a greater risk of ataxia, confusion, falls and injury [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Alberta Medical Association, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">PrescQIPP, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">BNF, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Wilson, 2019</a>]. <ul><li>A systematic review and meta-analysis looking at the association between z-drugs and fractures, falls and injuries in older adults (n=160,502) found a significant increased risk of injuries following treatment with zolpidem (OR = 2.05; CI 95%: 1.95–2.15) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Treves, 2018</a>]. </li></ul></li><li>Prolonged-release melatonin is licensed as monotherapy for the short-term treatment (maximum duration 13 weeks) of primary insomnia in people aged 55 years or over. Studies indicate that melatonin given for three weeks improves sleep onset latency and sleep quality in patients over 55 years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Wilson, 2019</a>]. <ul><li>Clinicians should discuss potential adverse effects (similar to other hypnotics) before prescribing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">BNF, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019a</a>]. </li></ul></li><li>Hypnotics should be avoided in pregnant women where possible and specialist advice sought if insomnia is causing significant distress and good sleep hygiene and lifestyle measures have failed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Alberta Medical Association, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">BMJ Best Practice, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Wilson, 2019</a>]. </li></ul><!-- end field 187e1464-5259-4bac-98bd-74541b051ad6 --><!-- end item 6575b1c7-4e93-4734-b7e3-234c36cad2dc -->","subChapters":[]},{"id":"a73d20e2-8cb0-5bf8-91ab-3eab833dc5d2","slug":"referral","fullItemName":"Referral","depth":4,"htmlHeader":"<!-- begin field 097f6724-bb7e-43c9-bc8c-ab5000f44e93 --><h4>When should I refer to secondary care?</h4><!-- end field 097f6724-bb7e-43c9-bc8c-ab5000f44e93 -->","summary":null,"htmlStringContent":"<!-- begin item 1a6b527f-c259-4da4-8ae7-ab5000f44e24 --><!-- begin field f0eebb73-c850-465d-90f3-ab5000f44e93 --><ul><li><strong>Refer the person to a sleep clinic, specialist with expertise in sleep medicine or neurology if:</strong><ul><li>Another sleep disorder (such as a parasomnia, narcolepsy, or obstructive sleep apnoea) is suspected — for more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/obstructive-sleep-apnoea-syndrome/\">Obstructive sleep apnoea syndrome</a> and <a class=\"topic-reference external-reference\" href=\"/topics/sleep-disorders-shift-work-jet-lag/\">Sleep disorders - shift work and jet lag</a>. </li><li>There is doubt regarding the diagnosis.</li></ul></li><li><strong>Seek specialist advice/consider referral to secondary care if:</strong><ul><li>Treatment in primary care has failed.</li><li>Insomnia occurs in a person from an occupational at-risk group, for example professional drivers.</li></ul></li><li><strong>Do not routinely refer adults with insomnia, jerks on falling asleep or isolated brief episodes of sleep paralysis.</strong></li></ul><!-- end field f0eebb73-c850-465d-90f3-ab5000f44e93 --><!-- end item 1a6b527f-c259-4da4-8ae7-ab5000f44e24 -->","subChapters":[{"id":"83794a9c-4fd5-5814-bd48-6c920d76fa75","slug":"basis-for-recommendation-9e8","fullItemName":"Basis for recommendation","depth":5,"htmlHeader":"<!-- begin field 92b6923b-5f67-4a23-81f8-ab5000f49c82 --><h5>Basis for recommendation</h5><!-- end field 92b6923b-5f67-4a23-81f8-ab5000f49c82 -->","summary":null,"htmlStringContent":"<!-- begin item 9e830988-5bdd-4197-8104-ab5000f49c4f --><!-- begin field 9ab71ed6-6ee4-44d8-806e-ab5000f49c82 --><p>The recommendations on when to refer a person with insomnia to secondary care are based on the clinical guidelines <em>Assessment to management of adult insomnia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Alberta Medical Association, 2015</a>], <em>European guideline for the diagnosis and treatment of insomnia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Riemann, 2017</a>] and <em>Suspected neurological conditions: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019b</a>], the Australasian Sleep Association position statement on <em>The use of psychological/behavioral treatments in the management of insomnia in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Ree, 2017</a>], the British Association for Psychopharmacology consensus statement<em> Evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Wilson, 2019</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Cunnington, 2016</a>]. </p><ul><li>The National Institute for Health and Care Excellence (NICE) recommends referring adults with suspected narcolepsy, with or without cataplexy for neurological assessment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019b</a>]. <ul><li>Symptoms suggestive of narcolepsy include excessive daytime sleepiness, hypnagogic hallucinations, sleep paralysis and cataplexy. Cataplexy should be suspected in people presenting with transient muscle weakness triggered by emotion (for example, laughter, anger and grief) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019b</a>]. </li></ul></li><li>NICE guidance recommends referring (for neurological assessment) adults with persistent symptoms suggestive of sleep behaviour disorders such as agitated or violent movements that are more complex than a simple jerking motion [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019b</a>]. </li><li>NICE guidance recommends against routine referral for:<ul><li>Adults with insomnia as this should be addressed by improved sleep hygiene in the community [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019b</a>]. </li><li>Adults with jerks on falling asleep or isolated brief episodes of sleep paralysis. Brief involuntary movements in sleep (such as hypnic jerks, which happen when falling asleep and being jerked awake) are common, do not indicate an underlying neurological disease and do not need referral unless severe — sleep hygiene measures may help. Isolated brief episodes of sleep paralysis are also benign but should prompt enquiry about symptoms of narcolepsy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">NICE, 2019b</a>]. </li></ul></li><li>CKS expert reviewers agreed that referral to a sleep clinic (where available) or a specialist with expertise in sleep disorders was appropriate:<ul><li>When a sleep disorder is suspected, to enable accurate diagnosis.</li><li>When insomnia has not responded to management in primary care, for a full review of the diagnosis and consideration of further treatment options — expert opinion in clinical guidance is that a 6–12 week trial of treatment is reasonable before considering referral [<a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Alberta Medical Association, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/insomnia/references/\">Cunnington, 2016</a>]. </li></ul></li></ul><!-- end field 9ab71ed6-6ee4-44d8-806e-ab5000f49c82 --><!-- end item 9e830988-5bdd-4197-8104-ab5000f49c4f -->","subChapters":[]}]}]}]}}},"staticQueryHashes":["3666801979"]}